Literature DB >> 19756494

[Treatment of postoperative thrombosis].

L-C Linke1.   

Abstract

For the treatment of deep vein thrombosis (DVT), rapid diagnosis and prompt therapy are crucial to minimize the risk of fatal pulmonary embolism and long-term complications, including the postthrombotic syndrome and recurrent thromboembolism. The treatment of acute DVT remains controversial. In this review, treatment options in relation to exposing and predisposing risk factors are discussed. Evidence-based data and recommendations from official guidelines are presented.

Entities:  

Mesh：

Year:  2009        PMID： 19756494     DOI： 10.1007/s00132-009-1451-5

Source DB:  PubMed          Journal:  Orthopade        ISSN： 0085-4530            Impact factor:   1.087


  36 in total

1.  Thrombolysis and pulmonary embolism presenting with cardiac arrest.

Authors:  R Manfredini; M Gallerani
Journal:  Arch Intern Med       Date:  2000 Dec 11-25

Review 2.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

3.  Heparin-induced thrombocytopenia associated with fondaparinux.

Authors:  Theodore E Warkentin; Brian T Maurer; Richard H Aster
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

4.  A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.

Authors:  H Decousus; A Leizorovicz; F Parent; Y Page; B Tardy; P Girard; S Laporte; R Faivre; B Charbonnier; F G Barral; Y Huet; G Simonneau
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

5.  Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin.

Authors:  H Partsch; W Blättler
Journal:  J Vasc Surg       Date:  2000-11       Impact factor: 4.268

Review 6.  Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

Authors:  B A Hutten; H R Büller; M H Prins
Journal:  Cochrane Database Syst Rev       Date:  2000

7.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Theodore E Warkentin; Andreas Greinacher; Andreas Koster; A Michael Lincoff
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Enrico Bernardi; Sabina Villalta; Paola Bagatella; Antonio Girolami
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

9.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

10.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

Authors:  H R Büller; B L Davidson; H Decousus; A Gallus; M Gent; F Piovella; M H Prins; G Raskob; A E M van den Berg-Segers; R Cariou; O Leeuwenkamp; A W A Lensing
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.